This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Beyond Biotech, 5 ETFs Up At Least 10% in Q4
by Sanghamitra Saha
Apart from biotech, these ETFs are seeing solid momentum in the ongoing quarter.
Why Biotech ETFs are Surging to New Highs
by Neena Mishra
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Biotech ETFs Hit New Highs on Deal Activities
by Sweta Killa
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Biotech ETF (BBC) Hits a New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Top ETF Stories of November
by Sanghamitra Saha
Inside the key ETF events of the month of November.
Top & Flop ETFs of November
by Sweta Killa
November was kind to the stock market with major bourses logging the best monthly gain since June.
Biotech Tops in November: Best ETFs & Stocks
by Sweta Killa
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
Top and Flop ETFs of Last Week
by Sanghamitra Saha
Last week was downbeat for the broader market owing to uncertainty over the signing of the ???phase-one??? trade deal between the United States and China.
Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD
by Sweta Killa
Healthcare bounced back with an outperformance starting the fourth quarter.
S&P 500 at Record High: 6 ETF Winners of Last Week
by Sweta Killa
The S&P 500 hit record highs last week, with the index rising for the fourth consecutive week, marking its longest winning streak since March.
Healthcare ETFs Win in October: Here's Why
by Sweta Killa
The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.
Biotech ETFs Surge on a Flurry of Positive News
by Sweta Killa
The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.
Trump Proposes 2020 Budget: ETFs to Top & Flop
by Sweta Killa
Here are the key takeaways from the proposed 2020 budget and their expected impact on ETFs.
6 Wining ETF Areas From a Late Santa Rally
by Sanghamitra Saha
These sector ETFs have made the most of the start of this Santa Rally.
4 Worst ETF Areas of Q4
by Sanghamitra Saha
These ETF areas have been particularly painful in the bloodbath of the fourth quarter.
Healthcare ETFs Sink on JNJ News, ACA Ruling: What???s Ahead?
by Sweta Killa
Healthcare took a hit recently on Johnson & Johnson news and a federal judge ruling. The rough trading also spread into the ETF world.
Top and Flop ETFs at Half-Way Q4
by Sweta Killa
We have highlighted both the best and worst performing zones and their ETFs at halfway Q4.
ETF Areas That Spooked Investors in October
by Sanghamitra Saha
These ETF areas lost the most in the Halloween month and gave investors the chills.
Scared of a September Lull? Play 6 ETFs
by Sanghamitra Saha
These ETFs may perform well in ill-famed September due to solid fundamentals.
5 ETFs to Play in July
by Sanghamitra Saha
Investors may tap these five ETFs for gains as President Trump aims the first shot in the trade war.
5 Safe and Sound ETF Strategies for 2H
by Sweta Killa
After a bumpy ride in the first half of the year, global stocks are bouncing back despite the trade war fears.
How to Build a Winning ETF Portfolio Amid Trade War Fears
by Sweta Killa
We have highlighted some strategies that could prove extremely beneficial for investors in a choppy market.
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
by Sweta Killa
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
Why These Small Cap Biotech ETFs are Soaring
by Neena Mishra
These biotech ETFs have surged this year thanks mainly to tax reform, rising M&A and positive regulatory backdrop.
Best and Worst ETFs of Last Week
by Sweta Killa
Several ETFs saw a huge decline while a few stood tall in the market turbulence.